Surprisingly, a preclinical study showed that the administration of anti-CCL3 antibody has therapeutic effects on BD and alleviates clinical manifestations in a mouse model by increasing the expression of CCR1, which is the receptor for CCL3 (48). Here, CCL3 is linked to Behcet disease.